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Summary
Background: Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) are
at high risk of cardiovascular mortality, thus therapies to improve renal function should be
clinically investigated.
Methods and results: We divided consecutive patients with CVD and CKD (n = 19) into exercise
(n = 10) and non-exercise (n = 9) therapy groups. Exercise therapy for 12 weeks signiﬁcantly
improved the anaerobic metabolic threshold (AT-V˙O2) and high-density lipoprotein cholesterol
(HDL-C) levels, and reduced triglyceride levels. Exercise therapy also improved estimated
glomerular ﬁltration rate (eGFR). Change in eGFR correlated signiﬁcantly and positively with
change in AT-V˙O2 and HDL-C, and negatively with change in triglyceride levels.
Conclusions: Exercise therapy correlates with improving renal function in CVD patients with CKD
through modifying lipid metabolism. Exercise therapy could be an effective clinical strategy to
f Car
improve renal function.
© 2010 Japanese College o∗ Corresponding author. Tel.: +81 96 373 5175;
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ntroductionatients with cardiovascular disease (CVD) and chronic kid-
ey disease (CKD) are at high risk of cardiovascular mortality
1], thus therapies designed to prevent or improve renal
unction are clinically important. While the importance of
Published by Elsevier Ireland Ltd. All rights reserved.
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Table 1 Baseline characteristics. There was no signiﬁcant difference in baseline characteristics between two groups at study
entry in all parameters.
Non-ET (n = 9) ET (n = 10) p-value
Age (years) 71.1± 13.8 72.3± 8.5 0.827
Male, n (%) 9 (100%) 8 (80%) 0.168
Body mass index (kg/m2) 26.0± 2.7 24.2± 4.6 0.302
Systolic blood pressure (mmHg) 127.7± 22.4 122.4± 18.9 0.590
Diastolic blood pressure (mmHg) 76.3± 9.7 68.8± 8.8 0.096
LVEF (%) 59.4± 10.1 58.7± 12.0 0.888
E/e′ 12.0± 3.1 13.7± 2.4 0.183
AT-V˙O2 10.7± 1.7 9.9± 1.9 0.372
BUN (mg/dl) 21.1± 3.7 21.3± 6.0 0.917
Creatine (mg/dl) 1.2± 0.2 1.2± 0.5 0.906
Triglyceride (mg/dl) 116.1± 63.3 114.6± 41.4 0.952
LDL-C (mg/dl) 93.2± 24.7 113.9± 31.6 0.129
HDL-C (mg/dl) 50.6± 15.9 40.6± 7.4 0.113
Risk factor (%)
Hypertension 9 (100%) 9 (90%) 1.000
Diabetes mellitus 2 (22%) 5 (50%) 0.350
Dyslipidemia 9 (100%) 8 (80%) 0.474
Smoking 1 (11%) 1 (10%) 1.000
Therapy distribution (%)
Anti-platelet drugs 7 (78%) 10 (100%) 0.211
ACE-I 2 (22%) 5 (50%) 0.350
ARB 7 (78%) 5 (50%) 0.350
-Blocker 4 (44%) 3 (30%) 0.650
Calcium channel blockers 4 (44%) 7 (70%) 0.370
Diuretic 2 (22%) 3 (30%) 1.000
Statin 7 (78%) 10 (100%) 0.211
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vET, exercise training; LVEF, left ventricular ejection fraction; E/e
velocity; AT-V˙O2, anaerobic metabolic threshold; BUN, blood ure
density lipoprotein cholesterol; ACE-I, angiotensin-converting enz
cardiac rehabilitation is recognized in recent clinical car-
diovascular therapies, we have experienced several CVD
patients with CKD who later showed improvement in renal
function in real clinical practice. Several animal studies have
demonstrated the beneﬁcial effects of exercise training on
renal function [2,3], and Moinuddin and Leehey recently
showed that aerobic exercise increases estimated glomeru-
lar ﬁltration rate (eGFR) in CKD patients [4].
Dyslipidemia is an independent risk factor for both CVD
and CKD. One study reported that dyslipidemia accelerates
the risk for CKD [5], thus we especially focus on the rela-
tionship between serum levels of lipid parameters and renal
function. The beneﬁcial effects of exercise therapy on lipid
metabolism in patients with CVD were also reported recently
[6]. The hypothesis tested in this study was that scheduled
exercise training improves renal function associated with
changes in serum lipids in CVD patients with CKD.
MethodsThe study protocol was approved by the Institutional
Review Board and written informed consent was obtained
from each patient. This prospective open-labeled clin-
ical trial included 19 consecutive CVD patients with
f
f
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mo of early diastolic ﬂow velocity to early diastolic mitral annular
rogen; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-
inhibitors; ARB, angiotensin II receptor blocker.
KD (mean± SD, age 71.7± 11.0 years, 89% male, 89.5%
schemic heart disease, ejection fraction 59.0± 10.8%)
ivided into an exercise training (ET) group (n = 10, eGFR,
7.0± 13.7ml/min/1.73m2) and non-exercise training (non-
T) group (n = 9, eGFR, 47.9± 9.6ml/min/1.73m2). Consec-
tive patients with CVD and CKD (eGFR < 60ml/min/1.73m2)
ho agreed to join cardiac rehabilitation therapy were
llocated to ET group, and consecutive outpatients with
VD and CKD without daily habits of exercise were
llocated to the non-ET group. Exclusion criteria were:
nable to exercise; proteinuria≥ 1 g/day; rapidly progres-
ive glomerulonephritis; nephrotic syndrome; hemoglobin
1c≥ 8.0%; left ventricular ejection fraction < 30%; history
f low pulmonary function and lung disease; history of
epatic and renal disturbance. Patients in the ET group
erformed once-a-week in-hospital aerobic exercise (half-
n-hour bicycle ergometer) and home exercise (half-an-hour
aily walking referring to Borg index at 12—13) for 12 weeks.
lso both groups equally underwent comprehensive inter-
ention including diet therapy, mental support, counseling
or medication, education for cardiovascular disease except
or exercise intervention. In addition, at study entry and
2 weeks later, all patients underwent blood sampling and
ardiopulmonary exercise tests to determine the anaerobic
etabolic threshold (AT-V˙O2), one of the criteria of car-
144 K. Toyama et al.
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Rigure 1 Changes in AT-V˙O2 and lipid parameters. Regular exe
b—d). Data are mean± SD. AT-V˙O2, anaerobic metabolic thresho
DL-C, high-density lipoprotein cholesterol.
iopulmonary function. The eGFR was calculated using an
quation from the Modiﬁcation Diet in Renal Disease Study
or the Japanese population.
ardiopulmonary exercise test
ndividually optimized 5, 10, 15, 20 watt-up ramp protocol
xercise on an electromagnetically braked cycle ergome-
er (Well Bike BE-250, Cateye Co., Ltd., Osaka, Japan) with
lood pressure and heart rate monitoring was performed.
espiratory gas was sampled from a mouthpiece, and minute
entilation, carbon dioxide output, oxygen uptake, ventila-
ory equivalent for carbon dioxide, ventilatory equivalent
or oxygen were obtained breath by breath (Metamax3B,
ORTEX Biophysik GmbH, Leipzig, Germany). Using the
bove parameters, the single operator medical technolo-
ist who was blinded to each treatment group calculated
naerobic metabolic threshold (AT-VO2), criteria of exercise
olerance, and cardiopulmonary function.tatistical analysis
ll statistical analyses were carried out using SPSS statis-
ical software, version 11.0J (SPSS Inc., Chicago, IL, USA).
o compare the baseline characteristics of the two groups,
T
t
a
A
nsigniﬁcantly improved AT-V˙O2 (a) and modiﬁed lipid parameters
T, exercise training; LDL-C, low-density lipoprotein cholesterol;
ata were analyzed by Student’s t-test for unpaired data
nd Fisher’s exact test for categorical data. To analyze the
reatment effect over 12 weeks, a paired Student’s t-test
as performed. Association between eGFR and each AT-V˙O2,
riglyceride and high-density lipoprotein cholesterol (HDL-C)
as assessed using Pearson’s correlation coefﬁcient. Haz-
rd ratios, 95% conﬁdence intervals, and levels of statistical
igniﬁcance (p-value) were calculated. To determine the
ssociation between improvement in eGFR and each change
n HDL-C levels and exercise therapy, we adjusted for age
nd the change in triglyceride levels in the following mul-
ivariable linear regression analysis by the forced inclusion
odels; Model 1 included age, and the change in triglyc-
ride and HDL-C levels; Model 2 included age, the change
n triglyceride, and exercise therapy. Data are expressed
s mean± standard deviation and p < 0.05 was considered
tatistically signiﬁcant.
esultshere were no signiﬁcant differences in sex, age, medica-
ions, coronary risk factors, cardiac ultrasound parameters
nd AT-V˙O2 between the two groups at study entry (Table 1).
lso baseline renal function and lipid parameters were
ot signiﬁcantly different. Regular exercise for 12 weeks
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Figure 2 Changes in eGFR and each parameter showing signiﬁcant correlation with eGFR; (a) regular exercise signiﬁcantly
improved eGFR compared to non-ET group. (b) Correlation between the change in AT-V˙O2 and eGFR, (c) in triglyceride and eGFR
2 SD
ltrat
n
p
Rand (d) in HDL-C and eGFR. The curved lines in b—d represent ±
open circle shows non-ET group. eGFR, estimated glomerular ﬁ
training; HDL-C, high-density lipoprotein cholesterol.
signiﬁcantly improved AT-V˙O2 (Fig. 1a), and signiﬁcantly
changed all lipid parameters, with an increase in HDL-C
and decrease in triglycerides and LDL-C within normal limits
(Fig. 1b—d). On the other hand, exercise had no signiﬁcant
effect on arterial blood pressure and hematocrit levels in
either group. Exercise signiﬁcantly improved eGFR in the ET
2group (47.0± 13.7 to 55.2± 16.9ml/min/1.73m , p = 0.021)
but we could not ﬁnd any change in eGFR in the non-ET group
(47.9± 9.5 to 44.6± 8.2ml/min/1.73 m2, p = 0.082). There
was a signiﬁcant difference in the change in eGFR between
the two groups (Fig. 2a). The change in eGFR correlated sig-
T
w
a
p
rvalues of the regression line. Closed circle shows ET group, and
ion rate; AT-V˙O2, anaerobic metabolic threshold; ET, exercise
iﬁcantly and positively with the change in AT-V˙O2 (r = 0.785,
< 0.001, Fig. 2b).
enal function and lipid parametershe change in eGFR correlated signiﬁcantly and positively
ith the change in HDL-C (r = 0.535, p = 0.018, Fig. 2d),
nd negatively with the change in triglyceride (r =−0.513,
= 0.025, Fig. 2c). Two patients in the ET group showed a
emarkable increase in HDL-C levels, one patient demon-
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[12] Athyros VG, Kakaﬁka AI, Papageorgiou AA, Pagourelias ED,
Savvatianos SD, Elisaf M, Karagiannis A, Tziomalos K, Mikhai-46
trated HDL-C increased from 46mg/dl to 95mg/dl and
nother patient demonstrated from 44mg/dl to 78mg/dl
ithout a reduction in body weight, change in dietary habit,
nd lifestyle except for the exercise intervention. Each
hange in HDL-C (ˇ = 0.482, p = 0.045) and exercise interven-
ion (ˇ = 0.676, p = 0.006) was signiﬁcantly associated with
n increase in eGFR levels in adjusted multiple regression
nalysis for age and change in triglyceride.
iscussion
ost patients with CKD and CVD tend to be forced to
ive with limited activity. Although exercise is not strongly
ecommended clinically for CKD patients, our study demon-
trated the beneﬁcial effects of exercise training, especially
n renal function, in patients with CVD and CKD.
It is reported that CKD patients typically show high
riglyceride and low HDL-C levels and this accelerates the
rogression of CKD [7,8]. Several experimental studies in
yper-lipidemic CKD mice [9,10] reported that dyslipidemia
ontributes to renal tissue injury such as glomerulosclero-
is, by increasing reactive oxygen species-induced activation
f nuclear factor kappa B and subsequent elevation of
nterleukin-6. In general, exercise increases HDL-C and
ecreases triglyceride levels [11], and our present study
emonstrated similar results. Serum HDL-C increase has
een shown to contribute to renal function improvement
12], and thus elevating HDL-C levels by exercise ther-
py could improve renal function in CKD patients. It has
lso been reported that exercise can prevent progressive
enal dysfunction through improvement of hyperlipidemia
n a nephritic rat model [3]. Multivariate regression analy-
is demonstrated an independent association between the
ncrease in HDL and improvement in eGFR in the present
tudy, indicating the importance of elevating HDL by exer-
ise therapy. Our data suggest the potential clinical beneﬁts
hat regular exercise with increased cardiopulmonary func-
ion can correlate with improving renal function through
odifying lipid metabolism, particularly HDL elevation.
The contribution of the change in blood pressure for an
mprovement in eGFR is not denied, however our results
howed no signiﬁcant change in blood pressure in the ET and
on-ET groups. Unfortunately, albuminuria, an independent
isk factor for CVD, and other metabolic parameters were
ot analyzed properly in the present pilot study, and thus
ffects of exercise therapy on these parameters and renal
unction need to be determined in future studies.
imitations
here are several limitations to the present study. First, this
tudy had a small sample size. Second, the baseline levels
f HDL-C in the ET group were apparently lower than in the
on-ET group. However, the change in levels of HDL-C was
igniﬁcantly associated with the change in eGFR in adjusted
orced multiple regression models including the baseline lev-
ls of HDL-C (ˇ = 0.589, p = 0.017). Therefore, there are no
igniﬁcant associations with the difference in baseline levels
f HDL-C and the present primary results.
To conclude the sufﬁcient importance associated with
xercise and renal function, further large trials are required.K. Toyama et al.
owever, the aim of this pilot study was to determine the
eneﬁcial effects between exercise and renal dysfunction,
nd we believe the present study is a valuable report pro-
oting further investigation.
onclusion
ur 12-week exercise intervention resulted in a signiﬁcant
mprovement in renal function in CVD patients with CKD.
his improvement was partially correlated with modifying
ipid metabolism and cardiopulmonary function. Exercise
herapy could be an effective clinical strategy to prevent
ardiovascular complications through the additional beneﬁts
n renal function.
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